Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Enfermedad de Parkinson y Parkinsonismo Parkinson’s disease & Parkinsonism 2534 artículos Viendo del 1 al 40 de 2534 artículos
Pub MED

Efficacy of deep brain stimulation of the subthalamic nucleus on autonomic dysfunction in patients with Parkinson's disease.NUEVO

Pietraszko W, Furgala A, Gorecka-Mazur A, Thor P, Moskala M, Polak J, Surowka AD, Krygowska-Wajs A.
Folia Med Cracov. 2013;53(2):15-22.
Pub MED

Visual feedback training using WII Fit improves balance in Parkinson's disease.NUEVO

Zalecki T, Gorecka-Mazur A, Pietraszko W, Surowka AD, Novak P, Moskala M, Krygowska-Wajs A.
Folia Med Cracov. 2013;53(1):65-78.
Pub MED

A network view on Parkinson's disease.NUEVO

Chandrasekaran S, Bonchev D.
Comput Struct Biotechnol J. 2013 Jul 14;7:e201304004. doi: 10.5936/csbj.201304004.
Pub MED

A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.NUEVO

Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ.
F1000Res. 2013 Jul 9;2:150. doi: 10.12688/f1000research.2-150.v1.
Pub MED

[Depression in Parkinson's disease].NUEVO

Murata M, Okamoto T.
Nihon Ronen Igakkai Zasshi. 2013;50(6):752-4. Japanese.
Pub MED

Furthering our understanding of the needs of adolescent children of parents with Parkinson's disease.NUEVO

Morley D, Jenkinson C.
Adolesc Health Med Ther. 2013 Jul 29;4:75-7. doi: 10.2147/AHMT.S47878.
Pub MED

[The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].NUEVO

Titova NV, Katunina EA.
Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(12):105-12. Review. Russian. No abstract available.
Pub MED

Total HIP arthroplasty in patients with Parkinson's disease.NUEVO

Mathew PG, Sponer P, Kucera T, Grinac M, Knízek J.
Acta Medica (Hradec Kralove). 2013;56(3):110-6.
Pub MED

A comparison between stereotactic targeting methods of the subthalamic nucleus in cases with Parkinson's disease.NUEVO

Savas A, Bozkurt M, Akbostancı C.
Acta Neurochir Suppl. 2013;117:35-41. doi: 10.1007/978-3-7091-1482-7_6.
Pub MED

Functional neurosurgery in Parkinson's disease: a long journey from destruction over modulation towards restoration.NUEVO

Nikkhah G, Carvalho GA, Pinsker M.
Acta Neurochir Suppl. 2013;117:5-11. doi: 10.1007/978-3-7091-1482-7_2.
Pub MED

Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.NUEVO

Korecka JA, Eggers R, Swaab DF, Bossers K, Verhaagen J.
Restor Neurol Neurosci. 2013;31(2):155-67. doi: 10.3233/RNN-110222.
Pub MED

Retinal nerve fiber layer thinning in dementia associated with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.NUEVO

Moreno-Ramos T, Benito-León J, Villarejo A, Bermejo-Pareja F.
J Alzheimers Dis. 2013;34(3):659-64. doi: 10.3233/JAD-121975.
Pub MED

Infections as a risk factor for Parkinson's disease: a case-control study.NUEVO

Vlajinac H, Dzoljic E, Maksimovic J, Marinkovic J, Sipetic S, Kostic V.
Int J Neurosci. 2013 May;123(5):329-32. doi: 10.3109/00207454.2012.760560.
Pub MED

On-shoe wearable sensors for gait and turning assessment of patients with Parkinson's disease.NUEVO

Mariani B, Jiménez MC, Vingerhoets FJ, Aminian K.
IEEE Trans Biomed Eng. 2013 Jan;60(1):155-8. doi: 10.1109/TBME.2012.2227317.
Pub MED

[Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].NUEVO

Pagonabarraga J, Rodríguez-Oroz MC.
Rev Neurol. 2013 Jan 1;56(1):25-34. Review. Spanish.
Pub MED

Screening for adhesive capsulitis in the timely diagnosis of Parkinson's disease.NUEVO

Rana AQ, Khara M, Wasim M, Dogar T, Alenazi B, Qa'aty N.
Can J Neurol Sci. 2013 Jan;40(1):123-5. No abstract available.
Pub MED

Serum urate and the risk of Parkinson's disease: results from a meta-analysis.NUEVO

Shen C, Guo Y, Luo W, Lin C, Ding M.
Can J Neurol Sci. 2013 Jan;40(1):73-9.
Pub MED

Nonmotor symptoms in drug-induced parkinsonism and drug-naïve Parkinson disease.NUEVO

Kim JS, Youn J, Shin H, Cho JW.
Can J Neurol Sci. 2013 Jan;40(1):36-41.
Pub MED

Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.NUEVO

Fagerlund K, Anderson LC, Gurvich O.
Am J Nurs. 2013 Jan;113(1):26-35; quiz 36. doi: 10.1097/01.NAJ.0000425744.76107.9f.
Pub MED

Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment.NUEVO

Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C.
Behav Neurol. 2013 Jan 1;27(4):501-13. doi: 10.3233/BEN-129025. Review.
Pub MED

Alexithymia and apathy in Parkinson's disease: neurocognitive correlates.NUEVO

Bogdanova Y, Cronin-Golomb A.
Behav Neurol. 2013 Jan 1;27(4):535-45. doi: 10.3233/BEN-129021.
Pub MED

Apathy and related executive syndromes in dementia associated with Parkinson's disease and in Alzheimer's disease.NUEVO

Grossi D, Santangelo G, Barbarulo AM, Vitale C, Castaldo G, Proto MG, Siano P, Barone P, Trojano L.
Behav Neurol. 2013 Jan 1;27(4):515-22. doi: 10.3233/BEN-129023.
Pub MED

Dopamine dysregulation syndrome in Parkinson's disease patients with unsatisfactory switching from immediate to extended release pramipexole: a further clue to incentive sensitization mechanisms?NUEVO

Solla P, Cannas A, Corona M, Marrosu MG, Marrosu F.
Behav Neurol. 2013 Jan 1;27(4):563-6. doi: 10.3233/BEN-129026.
Pub MED

Compulsive drumming induced by dopamine agonists in Parkinson's disease: Another aspect of punding.NUEVO

Vitale C, Trojano L, Barone P, Errico D, Agosti V, Sorrentino G, Grossi D, Santangelo G.
Behav Neurol. 2013 Jan 1;27(4):559-62. doi: 10.3233/BEN-129024.
Pub MED

Impulse control disorders in Parkinson's disease: crossroads between neurology, psychiatry and neuroscience.NUEVO

Bugalho P, Oliveira-Maia AJ.
Behav Neurol. 2013 Jan 1;27(4):547-57. doi: 10.3233/BEN-129019. Review.
Pub MED

Parkinson disease psychosis: Update.NUEVO

Friedman JH.
Behav Neurol. 2013 Jan 1;27(4):469-77. doi: 10.3233/BEN-129016. Review.
Pub MED

Attentional networks in Parkinson's disease.NUEVO

Cristinzio C, Bononi M, Piacentini S, Albanese A, Bartolomeo P.
Behav Neurol. 2013 Jan 1;27(4):495-500. doi: 10.3233/BEN-129020.
Pub MED

Neuropsychological and emotional correlates of personality traits in Parkinson's disease.NUEVO

Koerts J, Tucha L, Leenders KL, Tucha O.
Behav Neurol. 2013 Jan 1;27(4):567-74. doi: 10.3233/BEN-129017.
Pub MED

Towards a deeper comprehension of relationships among cognitive, behavioral and psychiatric symptoms in Parkinson's disease.NUEVO

Trojano L, Santangelo G, Conson M, Grossi D.
Behav Neurol. 2013 Jan 1;27(4):463-7. doi: 10.3233/BEN-129015. No abstract available.
Pub MED

Progressive micrographia shown in horizontal, but not vertical, writing in Parkinson's disease.NUEVO

Ma HI, Hwang WJ, Chang SH, Wang TY.
Behav Neurol. 2013;27(2):169-74. doi: 10.3233/BEN-120285.
Pub MED

Dual task performance in Parkinson's disease.NUEVO

Foley JA, Kaschel R, Sala SD.
Behav Neurol. 2013;27(2):183-91. doi: 10.3233/BEN-110238.
Pub MED

Loss of DJ-1 protein stability and cytoprotective function by Parkinson's disease-associated proline-158 deletion.NUEVO

Rannikko EH, Vesterager LB, Shaik JH, Weber SS, Cornejo Castro EM, Fog K, Jensen PH, Kahle PJ.
J Neurochem. 2013 Apr;125(2):314-27. doi: 10.1111/jnc.12126.
Pub MED

Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease.NUEVO

Barker RA, Barrett J, Mason SL, Björklund A.
Lancet Neurol. 2013 Jan;12(1):84-91. doi: 10.1016/S1474-4422(12)70295-8. Review.
Pub MED

AAV2-neurturin (CERE-120) for Parkinson's disease.NUEVO

Hickey P, Stacy M.
Expert Opin Biol Ther. 2013 Jan;13(1):137-45. doi: 10.1517/14712598.2013.754420. Review.
Pub MED

The role of the mitochondrial NCX in the mechanism of neurodegeneration in Parkinson's disease.NUEVO

Wood-Kaczmar A, Deas E, Wood NW, Abramov AY.
Adv Exp Med Biol. 2013;961:241-9. doi: 10.1007/978-1-4614-4756-6_20. Review.
Pub MED

[Subacute Parkinson's disease after suicide attempt with diazepam].NUEVO

Ukley B, Hermann W.
Nervenarzt. 2013 Feb;84(2):223-5. doi: 10.1007/s00115-012-3690-7. German. No abstract available.
Pub MED

Parkinson's disease-associated human P5B-ATPase ATP13A2 increases spermidine uptake.NUEVO

De La Hera DP, Corradi GR, Adamo HP, De Tezanos Pinto F.
Biochem J. 2013 Feb 15;450(1):47-53. doi: 10.1042/BJ20120739.
Pub MED

Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.NUEVO

Herrmann N, Marras C, Fischer HD, Wang X, Anderson GM, Rochon PA.
Drugs Aging. 2013 Jan;30(1):19-22. doi: 10.1007/s40266-012-0038-8.
Pub MED

Deep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson's disease.NUEVO

Favre E, Ballanger B, Thobois S, Broussolle E, Boulinguez P.
Neurotherapeutics. 2013 Jan;10(1):154-67. doi: 10.1007/s13311-012-0166-1.
Pub MED

Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.NUEVO

Ziegler DA, Wonderlick JS, Ashourian P, Hansen LA, Young JC, Murphy AJ, Koppuzha CK, Growdon JH, Corkin S.
JAMA Neurol. 2013 Feb;70(2):241-7. doi: 10.1001/jamaneurol.2013.597.
Viendo del 1 al 40 de 2534 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.